|
9. Stockholders' Equity (Details Narrative) (USD $)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
|
| Stock issued for equity investment | $ 10,811,196us-gaap_StockIssuedDuringPeriodValueNewIssues | |
| Research and development expense | 6,323,896us-gaap_ResearchAndDevelopmentExpense | 3,082,384us-gaap_ResearchAndDevelopmentExpense |
| SynBio Partner Warrants | ||
| Warrant issued to purchase common stock |
320,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_ClassOfWarrantOrRightAxis = xbio_SynBioPartnerWarrantsMember |
|
| Fair value of warrant at date of grant |
24,000us-gaap_WarrantsAndRightsOutstanding / us-gaap_ClassOfWarrantOrRightAxis = xbio_SynBioPartnerWarrantsMember |
|
| SynBio 2014 Warrant | ||
| Warrant issued to purchase common stock |
6,745,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_ClassOfWarrantOrRightAxis = xbio_Synbio2014WarrantMember |
|
| Fair value of warrant at date of grant |
506,000us-gaap_WarrantsAndRightsOutstanding / us-gaap_ClassOfWarrantOrRightAxis = xbio_Synbio2014WarrantMember |
|
| Baxter Healthcare | ||
| Stock issued for equity investment, shares |
10,695,187us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_BaxterMember |
|
| Stock issued for equity investment |
10,000,000us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_BaxterMember |
|
| Warrant issued to purchase common stock |
4,588,298us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_BaxterMember |
|
| Fair value of warrant at date of grant |
932,000us-gaap_WarrantsAndRightsOutstanding / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_BaxterMember |
|
| FDS Pharma | ||
| Stock issued for services, shares |
3,244,784us-gaap_StockIssuedDuringPeriodSharesIssuedForServices / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_FDSPharmaMember |
|
| Research and development expense |
812,000us-gaap_ResearchAndDevelopmentExpense / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_FDSPharmaMember |
|
| Serum Institute Partner Warrant | ||
| Warrant issued to purchase common stock |
160,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_SerumInstitutePartnerWarrantMember |
|
| Fair value of warrant at date of grant |
24,000us-gaap_WarrantsAndRightsOutstanding / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_SerumInstitutePartnerWarrantMember |
|
| Non-employee director | ||
| Warrant issued to purchase common stock |
1,600,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_NonEmployeeDirectorMember |
|
| Fair value of warrant at date of grant |
240,000us-gaap_WarrantsAndRightsOutstanding / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_NonEmployeeDirectorMember |
|
| Serum Institute 2014 Warrant | ||
| Warrant issued to purchase common stock |
3,200,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_SerumInstitute2014WarrantMember |
|
| Fair value of warrant at date of grant |
$ 480,000us-gaap_WarrantsAndRightsOutstanding / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = xbio_SerumInstitute2014WarrantMember |
|
| X | ||||||||||
|
- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. No definition available.
|
| X | ||||||||||
|
- Definition
Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|